Average weight loss with prescription GLP-1 medications is often substantial: Semaglutide: roughly 1015% body weight reduction Tirzepatide: roughly 1525% in some studies That level of weight loss is dramatically beyond what most supplements can demonstrate
Currently, the SURPASS-CVOT trial is evaluating the impact of dulaglutide and tirzepatide on cardiovascular events in patients with T2D (NCT04255433)
When combined with changes in diet and exercise, this class of drugs outperforms other diabetes and obesity medications
Ozempic at JosephCareRX is advised for obese people with a BMI of 30 or higher, as well as for people with a BMI of 27 or higher who suffer from weight-related illnesses like dyslipidemia, type 2 diabetes, or hypertension
Tirzepatide does reduce liver fat, but not to this degree
Semaglutide GLP-1 has been shown to reduce visceral adipose tissue, or belly fat, in patients with obesity